Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MyVax Cancer Vaccine Failure Could Be Due To Active Comparator – Genitope

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A failed primary endpoint for Genitope's Phase III trial of follicular non-Hodgkin's lymphoma vaccine MyVax was due to a comparator group that was found to be active, the company said. The firm announced in a Dec. 20 conference call that its lead drug candidate MyVax elicited an immune response in just 40 percent of patients enrolled in the trial and failed to meet its primary endpoint of statistically significant progression-free survival compared to the control group

You may also be interested in...



R&D IN BRIEF

Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief

R&D IN BRIEF

Methylnaltrexone disappoints Wyeth; updates on cancer vaccines; More R&D news, in brief

Therapeutic Vaccine Trials Should Focus More On Patient Response – Study

A paradigm shift is needed in the field of therapeutic cancer vaccine trials that would evaluate patient response rather than tumor response, according to an analysis of prostate cancer vaccine trials in the July 1 issue of Clinical Cancer Research.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel